<DOC>
	<DOCNO>NCT02729103</DOCNO>
	<brief_summary>This study evaluate treatment pattern , mortality , healthcare resource utilization , cost patient prostate cancer bone metastasis ( primary objective ) . Additionally , study evaluate opioid/analgesic use among line therapy patient population ( secondary objective ) . The study descriptive nature mean provide great understand pattern therapy observe real-world clinical practice ( absence clear guideline recommendation regard treatment sequencing ) , contribute great understanding major cost driver ( thus better-informing payer ) , examine real-world mortality patient .</brief_summary>
	<brief_title>Treatment Patterns Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Subjects least one claim primary diagnosis prostate cancer ( International Classification Diseases ( ICD ) Clinical Modification ( CM ) 185.xx ) day prostate cancer claim : At least one inpatient claim primary secondary diagnosis indicate bone metastasis ( ICD 9 CM 198.5 Healthcare Common Procedure Coding System ( HCPCS ) code treatment indicative bone metastasis OR At least two outpatient claim primary secondary diagnosis indicate bone metastasis ( ICD 9 CM 198.5 HCPCS code treatment indicative bone metastasis , minimum 30 day claim . Subjects diagnosis cancer prostate cancer define presence one inpatient two outpatient claim primary secondary diagnosis malignant neoplasm ( ICD9CM 140.xx171.xx , 174.xx184.xx,186.xx195.xx,200.xx209.3x , 230.xx239.xx ) 12month preindex period . Subjects claim primary secondary diagnosis indicate bone metastasis ( ICD9CM 198.5 ) treatment indicative bone metastases 12month preindex period . Patients SRE 12month preindex period . Subjects without continuous enrollment least 12 month index date . Subjects without continuous eligibility least 6 month index date . Subjects female . Subjects negative cost . Subjects less 45 year age index date .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>